Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, (2), CD001162

Sulpiride for Schizophrenia

Affiliations
Review

Sulpiride for Schizophrenia

B G Soares et al. Cochrane Database Syst Rev.

Abstract

Background: The antipsychotic drug sulpiride was formulated over 20 years ago and was marked as having a low incidence of adverse effects and an effect on the negative symptoms of schizophrenia. This relatively inexpensive antipsychotic drug has a similar neuropharmacological profile to several novel atypical drugs.

Objectives: To estimate the clinical efficacy and tolerability of sulpiride.

Search strategy: Electronic searches of Biological Abstracts (1982-1997), CINAHL (1982-1998), Cochrane Schizophrenia Group's Register (March 1998), Cochrane Library (Issue 1, 1998), EMBASE (1980-1998), MEDLINE (1966-1998), PsycLIT (1974-1997), SIGLE (1994-1998), and Sociofile (1974-1997) were supplemented by reference searching, contacting authors and the manufacturers of sulpiride.

Selection criteria: All randomised or quasi-randomised clinical trials focusing on the use of different doses of sulpiride or comparing sulpiride to (i) placebo; (ii) typical antipsychotic drugs; or (iii) atypical antipsychotic drugs, for those with schizophrenia or serious mental illness were selected.

Data collection and analysis: Trials were reliably selected and quality rated. Data were independently extracted, by two reviewers (BGOS, MF), and analysed on an intention-to-treat basis. It was assumed that people who did not complete the follow up had no improvement. Authors of trials were contacted for additional and missing data. Relative risk (RR) and 95% confidence intervals (CI) of dichotomous data were calculated with the random effects model and weighted mean difference (WMD) was calculated for continuous data.

Main results: The review currently includes 18 studies (30 citations). Studies are generally small and of poor quality. Limited evidence suggests that there is little difference between sulpiride and other drugs although the incidence of side effects may be less for sulpiride. There are no clear findings relating to negative symptoms.

Reviewer's conclusions: Sulpiride may be an effective antipsychotic drug but evidence is limited and data relating to claims for its value against negative symptoms is not trial-based.

Similar articles

  • Amisulpride for Schizophrenia
    NE Mota et al. Cochrane Database Syst Rev (2), CD001357. PMID 12076408. - Review
    This systematic review confirms that amisulpride is an effective 'atypical' antipsychotic drug for those with schizophrenia. Amisulpride may offer a good general profile, …
  • Molindone for Schizophrenia and Severe Mental Illness
    A Bagnall et al. Cochrane Database Syst Rev (2), CD002083. PMID 10796464. - Review
    The strength of the evidence relating to this compound is limited, owing to small sample size, poor study design, limited outcomes and incomplete reporting. Molindone may …
  • Sulpiride Versus Placebo for Schizophrenia
    IM Omori et al. Cochrane Database Syst Rev (2), CD007811. PMID 19370694. - Review
    Sulpiride may be an effective antipsychotic drug but evidence of its superiority over placebo from randomised trials is very limited. Practice will have to use evidence f …
  • Sulpiride Versus Placebo for Schizophrenia
    J Wang et al. Cochrane Database Syst Rev (4), CD007811. PMID 24729184. - Review
    Sulpiride may be an effective antipsychotic drug but evidence of its superiority over placebo from randomised trials is very limited. Practice will have to use evidence f …
  • Olanzapine Versus Other Atypical Antipsychotics for Schizophrenia
    K Komossa et al. Cochrane Database Syst Rev (3), CD006654. PMID 20238348. - Review
    Olanzapine may be a somewhat more efficacious drug than some other second generation antipsychotic drugs. This small superiority in efficacy needs to be weighed against a …
See all similar articles

Cited by 12 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback